Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2000

View Archived Issues

AstraZeneca and Cellomics collaborate on accelerating drug discovery

EntreMed establishes angiogenesis collaboration with Children's Hospital of Boston

ArQule and Monsanto extend and expand agreement

Genotropin delivery device now available for long-term replacement therapy in GHD

NCI to initiate phase III trial of Neovastat in the U.S. and Canada

Immunomedics' bispecific fusion proteins covered by U.S. patent

Recently issued patent covers Neurogens new selective dopamine D4 ligands

Novel anticonvulsants in development at SmithKline Beecham

Selective GABA-A ligands synthesized at MS&D for use particularly as nonsedating anxiolytics

Yoshitomi announces upcoming name change

Phase I results support efficacy of rhVEGF in producing therapeutic angiogenesis

Pfizer presents new series of JAK3 inhibitors for autoimmune diseases

Thienodipyridines useful for inflammatory and immune disorders designed at Takeda

New inhibitors of cGMP-PDE in development at BMS for ED and cardiovascular conditions

Takeda reveals new GnRH antagonists in recently issued patent

SB-269970: a potent and selective 5-HT7 receptor antagonist ligand

StemCells reports first direct isolation of human brain stem cells

New findings enhance validity of preclinical models for evaluating LHRH peptide conjugates

DuPont Pharma to acquire Canadian rights to Mallinckrodt's nuclear medicine products

Glaxo Wellcome and NeuroSearch to develop NS-2389 for treatment of depression

Cellegy expands Anogesic clinical trial for reduction of pain in hemorrhoidectomy

Pharmacia & Upjohn launches Aromasin breast cancer therapy in the U.S.

Georgetown University to study Magainin's squalamine for diabetic retinopathy

New treatment for CF now available in U.K. pharmacies

Antiinflammatory factor identified in glucocorticoid-treated human monocytes

Boehringer Ingelheim brings new angiotensin II antagonist to market in U.K.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...